Psychotropic drug labeling: regulatory, pharmaceutical industry, and clinical issues and perspectives. a pharmaceutical industry perspective on drug labeling
Robinson, D.S.
Psychopharmacology Bulletin 30(1): 23-25
1994
ISSN/ISBN: 0048-5764 PMID: 7972625 Document Number: 426619
Document emailed within 1 workday
Related Documents
Modestin, J. 1970: Psychotropic drug therapy and pharmaceutical industry Arzneimittel-Forschung 20(7): 877-879Thomas, J.W. 1995: AHi perspectives: flexible drug labeling and its impact on the drug development process. Liability issues Journal of the American Veterinary Medical Association 207(7): 899-900; Discussion: 902-904
Apley, M.D. 1995: AHi perspectives: flexible drug labeling and its impact on the drug development process. Practical aspects of flexible labeling in feedlots Journal of the American Veterinary Medical Association 207(7): 901
Schacter, L.P.; Anderson, C.; Canetta, R.M.; Kelley, S.; Nicaise, C.; Onetto, N.; Rozencweig, M.; Smaldone, L.; Winograd, B. 1992: Drug discovery and development in the pharmaceutical industry Seminars in Oncology 19(6): 613-621
Zinn, W. 1973: Production and control in the pharmaceutical industry. Labeling, packaging and control of endproducts. Demands of directives for endproducts Pharmaceutica Acta Helvetiae 48(6): 309-321
Personeus, G.R.; Ascione, P. 1981: Preparation and use of drug master files in the pharmaceutical industry Journal of Parenteral Science and Technology: a Publication of the Parenteral Drug Association 35(2): 63-69
Kopf, R. 1980: Drug legislation 1976: cost analysis for the pharmaceutical industry Der Internist 21(6): 333-338
Watkins, E.S. 2012: How the pill became a lifestyle drug: the pharmaceutical industry and birth control in the United States since 1960 American Journal of Public Health 102(8): 1462-1472
Koritz, G.D. 1995: American Academy of Veterinary Pharmacology and Therapeutics: perspectives on the utility of flexible drug labeling. An AAVPT perspective: Part I Journal of the American Veterinary Medical Association 207(7): 875-876
Boutonnat, J.; Barbier, M.; Ronot, X.; Seigneurin, D. 2000: Nucleus labeling or membrane labeling for studying the proliferation of drug treated cells? Morphologie: Bulletin de l'Association des Anatomistes 84(265): 11-15
2011: Conflict of interest regarding clinical physicians'relationship with pharmaceutical industry Seishin Shinkeigaku Zasshi 112(11): 1115-1116
Maciá Martínez, M.A.; Cuena Boy, R.; Solera Santos, J. 1997: Experience in performing a clinical trial not promoted by the pharmaceutical industry Medicina Clinica 108(8): 314-315
Pai, M.; Colford, J.M. 2002: Clinical trials in India sponsored by the pharmaceutical industry: a proposal for reforms National Medical Journal of India 15(2): 93-96
Miyata, Y. 2010: Conflict of interest regarding clinical physicians' relationship with pharmaceutical industry and medical education Seishin Shinkeigaku Zasshi 112(11): 1136-1145
Salas, Sía.P.; Osorio F, M.; Vial C, P.; Rehbein V, A.María.; Salas A, C.; Beca I, J.Pablo. 2006: Conflicts of interest in clinical practice. Ethical analysis of some relationships with the pharmaceutical industry Revista Medica de Chile 134(12): 1576-1582
Schaefer, M. 1986: The position and perspective of education in the pharmaceutical profession concerning drug information Die Pharmazie 41(5): 357-358
Schwarting, J.S. 2000: The pharmaceutical industry--to whom is it accountable? New England Journal of Medicine 343(19): 1416; Discussion 1417
Kahn, M.F. 1984: More on rheumatology and the pharmaceutical industry Journal of Rheumatology 11(5): 717-718
Walker, A.M.; García Rodríguez, L.A.; Pérez Gutthann, S. 1992: Epidemiology and the pharmaceutical industry Medicina Clinica 98(12): 465-468
Aumonier, J. 2003: Action of the pharmaceutical industry Annales Pharmaceutiques Francaises 61(6): 378-382